Biostatistics 1:35-47 (2000)
© 2000 Oxford University Press
Linear regression analysis of censored medical costs
1 Department of Biostatistics, Box 357232, University of Washington, Seattle, WA 98195, USA danyu{at}biostat.washington.edu
This paper deals with the problem of linear regression for medical cost data when some study subjects are not followed for the full duration of interest so that their total costs are unknown. Standard survival analysis techniques are ill-suited to this type of censoring. The familiar normal equations for the least-squares estimation are modified in several ways to properly account for the incompleteness of the data. The resulting estimators are shown to be consistent and asymptotically normal with easily estimated variance–covariance matrices. The proposed methodology can be used when the cost database contains only the total costs for those with complete follow-up. More efficient estimators are available when the cost data are recorded in multiple time intervals. A study on the medical cost for ovarian cancer is presented.
Keywords: Censoring; Cost analysis; Economic evaluation; Health economics; Incomplete data; Medical care; Survival analysis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. O Soares, C. P Iglesias, J M. Bland, N. Cullum, J. C Dumville, E A. Nelson, D. J Torgerson, G. Worthy, and on behalf of the VenUS II team Cost effectiveness analysis of larval therapy for leg ulcers BMJ, March 19, 2009; 338(mar19_2): b825 - b825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Soares and J. C Dumville Critical appraisal of cost-effectiveness and cost-utility studies in health care Evid. Based Nurs., October 1, 2008; 11(4): 99 - 102. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Shea, B. G. Hammill, L. H. Curtis, L. A. Szczech, and K. A. Schulman Medical Costs of Abnormal Serum Sodium Levels J. Am. Soc. Nephrol., April 1, 2008; 19(4): 764 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ng, B. Hasan, N. Mittmann, M. Florescu, F. A. Shepherd, K. Ding, C. A. Butts, Y. Cormier, G. Darling, G. D. Goss, et al. Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non-Small-Cell Lung Cancer--A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., June 1, 2007; 25(16): 2256 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Polsky, J. A. Doshi, M. S. Bauer, and H. A. Glick Clinical Trial-Based Cost-Effectiveness Analyses of Antipsychotic Use Am J Psychiatry, December 1, 2006; 163(12): 2047 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Atun, Y Samyshkin, F Drobniewski, Y Balabanova, I. Fedorin, J Lord, and R. Coker Costs and outcomes of tuberculosis control in the Russian Federation: retrospective cohort analysis. Health Policy Plan., September 1, 2006; 21(5): 353 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Dominici and S. L. Zeger Smooth quantile ratio estimation with regression: estimating medical expenditures for smoking-attributable diseases Biostat., October 1, 2005; 6(4): 505 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Polsky, J. S. Mandelblatt, J. C. Weeks, L. Venditti, Y.-T. Hwang, H. A. Glick, J. Hadley, and K. A. Schulman Economic Evaluation of Breast Cancer Treatment: Considering the Value of Patient Choice J. Clin. Oncol., March 15, 2003; 21(6): 1139 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Cooper, A. J. Sutton, M. Mugford, and K. R. Abrams Use of Bayesian Markov Chain Monte Carlo Methods to Model Cost-of-Illness Data Med Decis Making, January 1, 2003; 23(1): 38 - 53. [Abstract] [PDF]
|
|
|
|
 |
|
 A R Willan, D Y Lin, R J Cook, and E B Chen Using inverse-weighting in cost-effectiveness analysis with censored data Statistical Methods in Medical Research, December 1, 2002; 11(6): 539 - 551. [Abstract] [PDF]
|
|
|
|
|
|
X.-H. Zhou Inferences about population means of health care costs Statistical Methods in Medical Research, August 1, 2002; 11(4): 327 - 339. [Abstract] [PDF]
|
|
|
|
 |
|
 S. D. Ramsey, C. M. Moinpour, L. C. Lovato, J. J. Crowley, P. Grevstad, C. A. Presant, S. E. Rivkin, K. Kelly, and D. R. Gandara Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer J Natl Cancer Inst, February 20, 2002; 94(4): 291 - 297. [Abstract] [Full Text] [PDF]
|
|